Novitas says Pacific Edge’s CxBladder tests are ‘not payable’

Novitas says Pacific Edge’s CxBladder tests are ‘not payable’
The company can continue to apply for renewed coverage. (Image: Pacific Edge)
Rebecca Howard
The long-awaited draft Local Coverage Determination from Novitas is not good news for Pacific Edge’s US business. According to the determination (LCD), “CxBladder tests are not reasonable and necessary to support positive outcomes in the management of bladder cancer and, therefore, are not payable”.In June 2023, Pacific Edge confirmed that the LCD from Novitas — its Medicare administrative contractor — meant its flagship Cxbladder test for bladder cancer didn’t meet the threshold required for coverage un...

More Markets

1,200 Air NZ flight attendants vote to take strike action
Markets

1,200 Air NZ flight attendants vote to take strike action

About 1,200 Air New Zealand cabin crew have voted to take strike action, the union says.The union said those who voted for strike action worked across international, domestic and regional routes and had been trying for months to get better pay and rosters.Michael Wood, director o...

Sanford profit surges 224% as debt falls and aquaculture lifts earnings
Markets

Sanford profit surges 224% as debt falls and aquaculture lifts earnings

Better cash flow and lower debt helped drive seafood company Sanford’s net profit up by 223.8% to $63.7 million in the September year.Revenue was steady at $584.1m, and Sanford’s earnings before interest and tax came to $102.1m, up 88%.Managing director David Mair said it was an...

Serko swells in India, GetThere adds $8.8m revenue
Markets

Serko swells in India, GetThere adds $8.8m revenue

CEO says result is strongest ever as shares soar more than 8% in early trading.

Fletcher Residential worth $850m ‘on a good day’
Infrastructure

Fletcher Residential worth $850m ‘on a good day’

Shareholders have been clear no asset sales should be on the cheap.